Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer

Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).

Who May Be Eligible (Plain English)

Who May Qualify: 1. Patients must be ≥18 years of age. 2. Provision of fully willing to sign a consent form prior to any study specific procedures. 3. diagnosed by tissue sample (biopsy-confirmed), unresectable stage IIIB/IIIC or stage IV NSCLC. 4. Genetic variants of tumor tissue detected by NGS. Who Should NOT Join This Trial: None. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Patients must be ≥18 years of age. 2. Provision of fully informed consent prior to any study specific procedures. 3. Histologically or cytologically confirmed, unresectable stage IIIB/IIIC or stage IV NSCLC. 4. Genetic variants of tumor tissue detected by NGS. Exclusion Criteria: None.

Treatments Being Tested

OTHER

No treatment is included in this protocol.

No drug intervention or tissue sampling will be included in this study.

Locations (1)

Hunan Province Tumor Hospital
Changsha, Hunan, China